Kyverna Therapeutics
Clinical trials sponsored by Kyverna Therapeutics, explained in plain language.
Cell therapy company focused on autoimmune diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- CAR t therapy takes on myasthenia gravis in major new trial Results expected Sep 2027 (estimated) May already have reported ↗ 🚀 Make-or-break
-
CAR t therapy takes on myasthenia gravis in major new trial
Disease control Recruiting nowThis study tests a new treatment called KYV-101, made from a patient's own immune cells, against standard immunosuppressive drugs for generalized myasthenia gravis. About 66 adults who have not responded to at least two prior therapies will be randomly assigned to receive either …
Phase 2/3 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
CAR T-Cell therapy: what happens years later?
Knowledge-focused Recruiting nowThis study follows about 70 people who have already received KYV-101, a CAR T-cell therapy, for autoimmune diseases like lupus and multiple sclerosis. Researchers will monitor participants for up to 15 years to track any delayed side effects, new cancers, or other health problems…
Sponsor: Kyverna Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC